Sign in
Taking people in New ZealandNo phase

Retreatment with the Nectero EAST System for abdominal aortic aneurysm

Tests treating an abdominal aortic aneurysm a second time with Nectero EAST System.

Key facts

Who runs it
Nectero Medical, Inc.
Where
Auckland, New ZealandSee the siteAlso in 1 other country, 1 site
Trial code
Registry title
Nectero EAST System Retreatment Study
Status
Recruiting
People taking part
10 people, planned
Started
3 Mar 2026
Expected to end
Feb 2029
Type of study
Interventional
Treatments tested
  • Nectero EAST System
Record updated
26 May 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with a small abdominal aortic aneurysm (a bulge in the main belly artery) who already had a first Nectero EAST System treatment under protocol CTP-001. They would receive a second treatment.

Age
21 to 85 years
Sex
Men and women. Women cannot be able to become pregnant (after menopause or sterilization).
Disease stage
Spindle-shaped aneurysm below the kidney arteries, caused by hardened arteries, without symptoms. Size ≤5.3 cm (2.1 in) in men, ≤4.8 cm (1.9 in) in women. Aneurysm neck ≥ 15 mm long and ≤ 29 mm wide. Total treated length not more than 130 mm. ASA grade 1 to 3. Life expectancy over two years.
Earlier treatment
Must have had a first Nectero EAST System treatment under protocol CTP-001. Cannot have had earlier surgical or endovascular repair of the aneurysm.

Main reasons for not taking part

  • Aneurysm that is ruptured, leaking, causing symptoms, infected, sac-shaped or growing fast
  • Heart attack within 6 months, stroke or TIA within 3 months, or active heart disease needing treatment
  • Kidney failure needing dialysis, creatinine >2.5mg/dL (221 µmol/L) or eGFR < 45 mL/min/1.73m2
  • Liver disease, cirrhosis, liver transplant or heavy alcohol use
  • Connective tissue disorders such as Marfan syndrome

The registry criteria, word for word

Show all 41 criteriaShow less

Who can take part

  • Received initial Nectero EAST System treatment under protocol CTP-001
  • Males and females ≥21 to ≤85 years of age. Females must be of non-childbearing potential (menopause or sterilization)
  • Subject understands the purpose of the trial, agrees to voluntarily participate in the trial, signs the informed consent and is willing to complete the follow-up according to the requirements of the protocol
  • Infrarenal atherosclerotic fusiform abdominal aortic aneurysm ≤5.3 cm (male) and ≤4.8 cm (female)
  • Infrarenal aortic neck ≥ 15 mm in length and ≤ 29 mm in diameter
  • Overall AAA treatment length (distal renal artery to distal inferior margin of the aneurysm) not to exceed 130 mm
  • Iliac and femoral artery access, vessel size and morphology allow endovascular access of 14F (or larger) introducer sheaths and catheters
  • Subject meets American Society of Anesthesiology (ASA) grade 1 through 3 criteria, inclusive
  • Subject has > two-year life expectancy
  • Subject is able and willing to comply with all required follow-up clinic visits including CT scans (screening, 6, 12, 24 months) and blood draws

Who cannot take part

  • Previous surgical or endovascular aneurysm repair for abdominal aortic aneurysm
  • Subject has had a myocardial infarction within six (6) months prior to enrollment or elevated CK enzymes or troponin indicative of an evolving MI prior to procedure
  • Subject has undergone other major surgery within the 30 days prior to enrollment
  • Known contraindication to undergoing angiography or receiving systemic anticoagulation during the procedure
  • Subject is participating in another research trial that could interfere with the results of the trial (e.g., drug trial)
  • Subjects with rapidly expanding AAA (previous diameter increases of ≥0.5 cm in 6-months or ≥1 cm in 1 year) as these should be evaluated for immediate repair
  • Subject has a mycotic or infected aneurysm
  • Subject has current angina, unstable angina, or other active cardiac condition such as congestive heart failure III and IV, atrial arrhythmia, ventricular arrhythmia, or valvular disease, requiring intervention
  • Subjects with any transient ischemic attack (TIA) or ischemic stroke within 3 months
  • Known allergy to contrast material that cannot be adequately premedicated, delivery system materials (i.e., nylon, polyurethane) and/or pentagalloylglucose (PGG)
  • Subject is morbidly obese or has other clinical conditions that severely inhibit X-ray visualization of the aorta
  • Subject has connective tissue/collagen disorder (e.g., Marfan syndrome, vascular Ehlers-Danlos Syndrome, Loeys-Dietz Syndrome, Eaton Syndrome, Bessel-Hagen disease, etc.)
  • Subject has active systemic infection
  • Subjects with active/acute or a history of unstable chronic liver disease or current liver disease including but not limited to liver transplant, known genetic disorders such as Gilbert syndrome or other liver diseases
  • Subjects with uncontrolled alcohol use disorder or current alcohol use putting them at risk of liver disease: including consumption of above one standard drink per day for women and two standard drinks per day for men
  • Subjects with known right-sided heart failure or pathologically dilated inferior vena cava or hepatic veins indicative of congestive hepatopathy
  • Subject has dialysis dependent renal failure or baseline serum creatinine level >2.5mg/dL or eGFR < 45 mL/min/1.73m2
  • Subjects with aminotransferase (ALT and/or AST) which is ≥1.5x upper limit of normal (ULN) or TB is out of normal range for the evaluating laboratory
  • Subjects with INR out of normal range for the evaluating laboratory for a subject not on anti-coagulant therapy; or INR >3 for a subject on anti-coagulant therapy
  • Subject has an acutely ruptured, leaking, dissecting or emergent aneurysm
  • Subject has a symptomatic infrarenal abdominal aortic aneurysm
  • Subject has current vascular injury due to trauma
  • Subject's aneurysm is thoracic, suprarenal or juxtarenal
  • Subject has anatomy of diffuse, ulcerated, or extensive (shaggy) thrombus in the neck of the AAA, that in the opinion of the vascular surgeon/investigator, could result in embolization of the thrombus
  • Subject has anatomy of calcification, and/or plaque within the ilio-femoral arteries or severe infrarenal neck angulation that may compromise or does not allow delivery of the Introducer Sheath or the delivery catheter of the Nectero EAST System
  • Subject has other medical, social, or psychological problems that, in the opinion of the investigator, preclude them from participation in the trial and to undergo the procedures and evaluations pre- and post-treatment
  • Subjects that may not tolerate the lowering of their systolic blood pressure to approximately 100mmHg, should not be considered for this study or treated using the Nectero EAST System
  • Subjects that may not be able to tolerate transient occlusion of the aorta should not be considered for this study
  • Subjects with saccular AAA
  • Subjects who are not suitable for the Nectero EAST System treatment, as determined by the investigator
  • Subjects with cirrhosis (e.g., known history or new clinical diagnosis by elastography with a fibrosis score of F3 or F4 and/or steatosis grade of S3)

The main criteria, as questions

These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Are you between 21 and 85 years old?

This trial is currently available in New Zealand.

Also in 1 other country, 1 site

  • Auckland City HospitalAuckland, New ZealandContact: Cynthia CorneTaking people

About the trial

What the trial wants to find out

This is an exploratory pilot study to evaluate the safety and clinical utility of retreatment with an investigational combination product called the Nectero EAST System to treat Abdominal Aortic Aneurysms or AAA.

The group in the trial

  • InterventionalTreatment being tested

    Use of the EAST System for the stabilization treatment of AAA. The device is delivered endovascularly and placed in the AAA sac to deliver the Stabilizer Infusion Solution.

    Treatment: Nectero EAST System

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Clinical Pilot Study to Evaluate the Safety and Clinical Utility of Retreatment With the Nectero EAST System for Stabilization of Abdominal Aortic Aneurysms
Plain-language title
Retreatment with the Nectero EAST System for abdominal aortic aneurysmGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Criteria questions
Built from NCT07505082, who can take part
Record updated
26 May 2026